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Patients with multiple sclerosis often require high levels of medical 
input from their GP and treating neurologist. GPs are often their first 
point of contact regarding symptoms or complications of their disease 
or its treatment.
M
ultiple sclerosis (MS) is an inflamma-
tory demyelinating disease of the 
central nervous system (CNS) that 
affects an estimated 25,000 individuals 
in Australia, or about 0.1% of the population. 
The disease typically starts in early adulthood, 
and affects females approximately twice as often 
as males. In young adults, MS is the most com-
mon cause of neurological disability. The aeti-
ology of MS is unknown; however, genetic as 
well as environmental factors such as infections, 
low sunlight exposure and vitamin D deficiency 
might be involved. Also, there is now unequivocal 
evidence for the  deleterious effects of cigarette 
smoking on MS (it has been shown to increase 
the rate of progression of MS by 3.6 times).
Due to the high prevalence of the disease, GPs 
are likely to be confronted with these patients 
on a regular basis. They therefore play an import-
ant role in the management of these patients, 
including early diagnosis of the condition and 
referral of patients to a neurologist. The GP also 
serves as the first contact point and source of 
information for patients with MS. Daily prob-
lems, most of which are consequences of long-
standing disease (e.g. spasticity, incontinence, 
pain, depression) are largely managed by the GP 
alone. Furthermore, the GP must be aware of 
the side effects and complications of the disease- 
modifying therapies used to treat MS. 
This article focuses on the diagnosis of MS 
and also provides an overview on the presently 
available therapies and their side effects. Clinical 
and MRI presentations of MS and its pathology 
are also discussed. 
HOW DO PATIENTS WITH MS PRESENT?
The plaques of MS can occur anywhere in the 
CNS, and therefore MS may present with a wide 
range of symptoms. These can include disturbed 
vision (if the plaque is in the optic nerve), loss of 
balance (due to a plaque in the cerebellum), and 
numbness, weakness or incontinence (caused 
by a plaque in the spinal cord). Most plaques are 
asymptomatic, with only about one in 15 causing 
clinical symptoms.
The clinically isolated syndrome, CIS
The first clinical episode in which a previously 
healthy person has symptoms and signs sug-
gestive of MS is called a ‘clinically isolated 
 syndrome, or CIS. It usually occurs in young 
adulthood and the most commonly affected 
areas are the optic nerves, brainstem, cerebellum 
Key points
• The diagnosis of multiple 
sclerosis (MS) is based on 
the principle that MS 
plaques develop on more 
than one occasion (dissemi­
nation in time) and in more 
than one part of the CNS 
(dissemination in space).
• MS cannot be diagnosed 
with MRI alone; clinical 
signs and symptoms must 
also be present.
• As a general rule, initiation 
of therapy in MS is a 
decision for the neurologist. 
The GP has a pivotal role in 
co­management.
• Immunomodulatory 
therapies cannot alleviate 
already existing MS 
symptoms. They merely 
prevent the development of 
acute relapses.
• Symptoms can influence 
each other in a negative 
way: for example, 
depression negatively 
affects cognition, and 
increased effort to 
overcome a higher muscle 
tone in spasticity may 
increase fatigue.
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and spinal cord; the cerebral hemisphere is less 
often affected. The characteristics of a CIS are 
that the episode has an acute or subacute onset, 
lasts for at least 24 hours and occurs in the 
absence of fever or infection. Typically, patients 
recover from the symptoms after they reach 
their peak within two to three weeks. Usually a 
CIS is isolated in space (i.e. monofocal), which 
means that the patient has signs indicative for 
a lesion in a single area, and not in multiple areas. 
The features of a CIS suggestive of MS (typical 
features) and those for which other diagnoses 
should be considered (atypical features) are 
summarised in Table 1.
THE DISEASE COURSE
• A relapse is caused by a newly developing 
MS plaque and is defined as a period of 
 neurological worsening that lasts for at least 
24 hours and occurs in the absence of fever or 
infection.
Some patients with CIS never have a second 
area of demyelination, but if an episode sub-
sequently occurs anywhere in the CNS then 
that is a defining event for the development of 
MS. Although the clinical course of MS varies 
considerably between patients, in the majority 
(about 85%) of those with the condition, the 
two phases described below and in Figure 1 
can be distinguished.
The relapsing–remitting phase (RR–MS). This 
phase, which occurs at the beginning of the 
 disease, is characterised by episodes of neuro-
logical disability (so-called exacerbations, 
relapses or attacks) separated by periods of 
 recovery. In other words, disability due to the 
relapses resolves partly or completely in this 
phase. Relapses happen at random intervals, and 
occur on average about once per year, and steadily 
decrease thereafter. 
© KO STUDIOS 
Figure 1. Disability due to relapses of MS is likely to resolve in the relapsing–remitting phase of 
the disease. Permanent and irreversible disability predominantly occurs in the secondary–
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The secondary–progressive phase 
(SP–MS). About 90% of patients with 
 RR–MS progress to SP–MS within 25 years. 
This phase is characterised by steady 
 neurological worsening without recovery. 
Typically, relapses do not occur during this 
phase. Patients in this phase lose their 
 ability to walk independently and eventu-
ally become wheelchair or bed bound. 
Also, cognitive problems become more 
prominent. 
Other phases
A small group of patients with MS (10%) 
follow a primary progressive disease course 
(PP–MS), which is characterised by steady 
decline in  neurological functioning from 
the beginning. These patients usually pres-
ent with a gait  disorder and never experi-
ence relapses. 
About 5% of patients with MS suffer 
from a progressive disease course accom-
panied by acute attacks with or without 
recovery, which is referred to as progressive–
relapsing MS (PR–MS). 
WHAT CAUSES DISABILITY? 
• Axonal loss is the major cause of  
progressive and irreversible neurological 
deficit in MS.
The relapsing–remitting phase of MS 
is characterised by the development of 
acute MS plaques, which typically form in 
the corpus callosum, optic nerves, periven-
tricular region, juxtacortical region and 
the spinal cord. The cerebellum and brain-
stem may also be affected. In addition, MS 
plaques frequently develop in the grey 
matter, although MRI has a low sensitivity 
for these lesions. The acute plaque consists 
of an accumulation of lymphocytes and 
macrophages, in close proximity to degen-
erating myelin, leaving ‘nude’ nerve fibres 
(axons) in the affected area. During this 
process, variable numbers of axons are 
also damaged. This phase is followed by a 
reactive astrocytic scar formation, and 
after the inflammation subsides a ‘chronic 
inactive’ MS plaque develops. Both axonal 
damage and scar formation are irreversible 
and, furthermore, axonal loss continues 
MulTIPle SCleRoSIS CONTINUED 
TABLE 1. FeATuReS oF CIS TYPICAl AND ATYPICAl FoR MulTIPle SCleRoSIS
Typical for MS* Atypical for MS†
All cases of CIS
• Acute or subacute onset
• Last at least 24 hours
• Symptoms reach peak after three weeks
• Partial or complete recovery beginning 
after three weeks
• Most often monofocal
• Chronic/progressive onset
• Symptoms last less than 24 hours 
(e.g. minutes, seconds)
• Absence of recovery
• Symptoms in setting of fever or 
infection
optic nerve
• Optic neuritis in one eye, characterised 
by:
– mild pain on eye movement
– reduced visual acuity and colour 
vision
– normal or only mild disc swelling
– improvement within three weeks from 
onset
• Optic neuritis in both eyes at the 
same time, characterised by:
– complete loss of vision
– no recovery 
– chronic blurry vision
– painless or severe pain with visual 
loss
– scintillating scotoma for minutes
– photophobia
Brainstem/cerebellum
• Loss of balance
• Gaze evoked nystagmus
• Often more than one symptom (e.g. 
vertigo and facial numbness)
• Disturbed eye movements (weakness of 
eye muscles), double vision
• Fluctuating weakness of eye 
muscles (fluctuating double vision)
• Isolated facial pain
• Movement disorders (twitching 
eyelids, or forced closure of eye)
Spinal cord
• Lhermitte’s symptom
• Urinary or faecal incontinence
• Asymmetric weakness of limbs
• Altered sensation on one side of trunk 
or both legs
• Tingling everywhere
• Lateralised, marching tingling
• Numb hands at night












• Blindness in both eyes
Modified from Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol 2012; 11: 157-169.
ABBREVIATIONS: CIS = clinically isolated syndrome; MS = multiple sclerosis.
* These features of CIS are typical of an inflammatory demyelinating disorder of the CNS, such as MS.
† These features of CIS are not typical of an inflammatory demyelinating disorder of the CNS and other diagnoses 
should be considered. 
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after the acute inflammation subsides. 
Acute plaques cause a relapse if they 
develop in an eloquent area of the CNS; 
otherwise they stay clinically silent. A 
lesion is shown in Figure 2.
In the early stages of the disease, the 
brain is able to compensate for the damage 
of MS plaques and also variable remyelin-
ation occurs. In this phase, patients partly 
or completely recover from the symptoms 
of relapses. With increasing damage, the 
compensatory mechanisms become 
exhausted and progressive and irreversible 
neurological deficits develop; the patient 
has entered the progressive phase of the 
disease. In this phase, acute lesions become 
less common and global change in the 
white matter, with diffuse axonal loss and 
inflammation, becomes the prominent 
feature of the disease. As a consequence of 
longstanding disease and axonal loss, the 
brain ‘shrinks’. Atrophy affects both the 
white matter and the grey matter, most 
likely has onset at the earliest stages of the 
disease, and is evident in later disease by 
the presence of wide sulci and ventricles 
and decreasing brain weight. 
STILL CIS OR ALREADY MS? HOW IS 
MS DIAGNOSED?
• The diagnosis of MS is based on the 
principle that MS plaques develop: 
– on more than one occasion, i.e. 
 dissemination in time
– in more than one part of the CNS , 
i.e.  dissemination in space.
Patients with CIS usually present with 
one episode in one part of the CNS – for 
example, the presenting symptom might 
be blurred vision due to a plaque in the 
optic nerve. The diagnosis of MS cannot 
be made until it is proven that the patient 
has had another MS plaque/episode in 
a different part of the CNS. If the same 
patient develops weakness due to a lesion in 
the cerebral hemispheres and at  least 
30 days between the onset of the weakness 
and optic neuritis can be distinguished 
Figure 2. Brain slice with a macro sco pically 
visible lesion in the subcortical white matter. 
The hallmark of MS are multiple, sharply 
demarcated ‘sclerotic’ plaques in the white 
matter. Some MS plaques can be seen with 
the naked eye. The lesions feel hard when 
touched, which is a consequence of the 
scar formed by astrocytes. This gave the 
disease its name: ‘sclerosis’ originates from 
the Greek word meaning ‘hard’.
DIAGNOSING MULTIPLE SCLEROSIS
For the diagnosis of MS, lesions or symptoms have to show dissemination in space (DIS) and time (DIT), as summarised below and in 
the Table: 
• if a patient has at least two clearly distinguishable episodes in two different anatomical locations of the CNS, a diagnosis of relapsing- 
remitting MS can be made  
• if a patient has only one episode affecting one site, either the presence of both DIS and DIT on MRI is necessary to confirm the diagnosis 
or a second attack has to be awaited.
TABle. WHAT IS NeeDeD To CoNFIRM A DIAGNoSIS oF MS?
Number of episodes First clinical episode Subsequent clinical episode Needed to confirm diagnosis
N DIT DIS
One episode One site affected None Yes Yes
Two or more sites 
affected
None Yes
Two episodes One site affected Different site affected Yes
One site affected Same site affected Yes
ABBREVIATIONS: DIS = dissemination in space; DIT = dissemination in time; N = no need for further confirmation.
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then dissemination in time and in space 
is  present and the diagnosis of RR–MS can 
be made (see the box on page 19). 
Magnetic resonance imaging (MRI)
• MS cannot be diagnosed with MRI 
alone; clinical signs and symptoms must 
also be present. 
The imaging technique MRI is the 
modality of choice for the assessment of 
patients with suspected MS. CT has a very 
limited sensitivity to detect MS lesions and 
is  therefore not used. MS lesions in typical 
locations are seen as hyperintense (bright 
compared with surrounding tissue) lesions 
on T2-weighted (including PD and FLAIR) 
magnetic resonance images. New so-called 
‘active’ lesions typically enhance after 
the administration of  gadolinium-based 
 contrast agents, and appear ‘bright’ on 
T1-weighted images (Figures 3 a to f). 
MRI may provide an earlier and more 
confident diagnosis in patients with 
CIS and can provide evidence for dissem-
ination in time and space. More than half 
of adults with CIS have multiple asymp-
tomatic brain lesions suggestive of MS. If 
lesions are  present, gadolinium-enhanced 
MRI may be useful to demonstrate dis-
semination in time. The MRI criteria for 
multiple sclerosis are shown in the box on 
this page. 
DIFFERENTIAL DIAGNOSIS
• Spinal cord MRI is often useful for:
– confirmation of dissemination 
in space
– exclusion of structural lesions in 
patients presenting with a cord 
syndrome
– clarification of the diagnosis in 
patients with an equivocal MRI  
of the brain.
Asymptomatic white matter lesions 
detected as T2 hyperintense lesions 
are  very frequent in a wide range of 
 diseases, including some that may mimic 
MS (see the box above). The MS 
MulTIPle SCleRoSIS CONTINUED 
Figures 3a to f. Typical MS lesions are round to ovoid in shape, from a few millimetres to 
more than a centimetre in diameter. a (top left). Multiple periventricular lesions, typically 
orientated perpendicular to the lateral ventricles (axial PD-weighted image). b (top centre). 
Infratentorial lesions (axial T2-weighted image). c (top right). Lesion in the dorsal aspect of 
the cervical spine. Typical spinal cord lesions are cigar shaped and eccentrically located, 
and do not involve the entire diameter of the medulla (sagittal T2-weighted image). d (bottom 
left). Juxtacortical lesions (sagittal FLAIR image). e (bottom centre). Contrast-enhanced 
active, juxtacortical lesion. Enhancement may be detectable up to eight weeks after 
formation of a new lesion (sagittal T1-weighted image with gadolinium). f (bottom right). 
Hypointense (dark) lesions on T1-weighted images are called ‘black holes’. They are 
characteristic for MS and if they persist longer than six months correspond to severe tissue 
damage and axonal loss (axial T1-weighted image).
MRI CRITERIA FOR MULTIPLE 
SCLEROSIS
Dissemination in space
• One or more asymptomatic T2 lesions 
in at least two of the following four 
 locations: juxtacortical, periventricular, 
infratentorial and spinal cord
Dissemination in time
• A new lesion visible on a follow-up 
scan when this is compared to a 
 previous scan obtained at any time 
after the onset of CIS
• A scan showing both gadolinium- 
enhancing and non-enhancing lesions 
that do not cause clinical signs
DIFFERENTIAL DIAGNOSIS OF 
MULTIPLE SCLEROSIS
other demyelinating diseases of 
the CNS
Including:
• Acute disseminated encephalomyelitis
• Neuromyelitis optica
• Idiopathic transverse myelitis
Inflammatory nondemyelinating 




• Systemic lupus erythematosus
Noninflammatory CNS diseases
Including:
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MRI criteria should therefore only be 
used in the clinical context of suspected 
MS or CIS. Non specific lesions, particu-
larly those that are small and subcortical, 
are frequently seen in otherwise normal 
healthy people. Because of the non-
specific nature of these lesions, ‘possible 
demy elination’ is often mentioned in 
radiol ogical reports, which can lead to an 
inappropriate and potentially harmful 
diagnosis of MS. 
Other investigations, such as lumbar 
puncture and evoked potentials, are not 
mandatory for the diagnosis of RR–MS 
but can help to exclude other diseases or 
confirm the diagnosis of demyelination. 
Routine blood tests are normal in patients 
with MS, but an autoimmune screen or 
investigations for infections are often 
 necessary to exclude MS mimics. 
THE THERAPY OF MS
As a general rule, initiation of therapy 
in patients with MS is a decision for the 
neurologist.  However, the GP has a pivotal 
role in co-management. 
If treatment of relapses is warranted, 
corticosteroids are used as the first-line 
therapy, followed by immunomodulatory 
therapies as necessary. 
Corticosteroids
Corticosteroids are used for the first-line 
treatment of relapses in patients with MS. 
Not every relapse mandates treatment, how-
ever, and if the patient’s symptoms are mild 
(e.g. paraesthesias), a watchful waiting 
period is usually appropriate. More signif-
icant symptoms (e.g. motor weakness or 
vision loss) may warrant the use of high-dose 
corticosteroid therapy. Most frequently, 
1000 mg intravenous methylprednisolone 
is used for three to five days. 
These drugs are potent anti-inflammatory 
agents that reduce oedema, stabilise the 
blood–brain barrier and may repair the 
regulatory function of immune cells. They 
accelerate recovery from the acute attack, 
but data on their effects on subsequent 
relapse and atrophy are lacking. 
Immunomodulatory therapies
Immunomodulatory or disease-modifying 
therapies are used as monotherapies in 
patients with relapsing MS to reduce the 
frequency and severity of clinical attacks. 
So far, no therapy has been proven effective 
for the purely progressive forms of MS. 
The treatments with the longest history 
(interferon beta and glatiramer acetate) 
have understandably been the most often 
used treatments for MS. Their advantage 
is their excellent safety profile; their disad-
vantage, their incomplete efficacy in some 
patients. In addition, compliance may be 
poor in some patients, usually secondary 
to poor tolerance. 
More recently introduced drugs (e.g. 
mitoxantrone, teriflunomide, fingolimod, 
natalizumab and dimethyl fumarate) may 
show greater efficacy in some patients but 
also possess greater safety concerns. Ideally, 
the optimal treatment would be the one 
with highest efficacy and least ‘treatment 
burden’ (i.e. side effects, tolerability, 
 convenience and safety). In practice, a 
TABLE 2. IMMuNoMoDulAToRY THeRAPIeS FoR MulTIPle SCleRoSIS
Drug Dosing Adverse effects Precautions
Interferon beta-1a Intramuscular injection: 30 µg 
IM once a week
Subcutaneous injection: 44 µg 
SC three times a week
Leukopenia, LFT abnormalities Baseline and follow-up LFTs and 
full blood count
Interferon beta-1b 8 mIU SC every other day Leukopenia, LFT abnormalities Baseline and follow-up LFTs and 
full blood count
Glatiramer acetate 20 mg SC daily Injection site reactions, 
systemic reactions
–
Natalizumab 300 mg IV once a month Progressive multifocal leuko-
encephalopathy
Immunodeficiency, JC virus 
positivity, cancer
Fingolimod 0.5 mg orally once daily Bradycardia with first dose, 
macular oedema, decreased  
forced expiratory volume, 
LFT abnormalities
Immunodeficiency, infections, 
cancer, diabetes, asthma, 
cardiac disease, hypertension, 
varicella zoster virus immunity
Teriflunomide 14 mg orally once daily Liver failure, neuropathy, 
leukopenia
Pregnancy, LFTs, basal cell 
carcinoma
Dimethyl fumarate 240 mg orally twice daily Flushing, gastrointestinal 
symptoms
Baseline and annual full blood 
count
ABBREVIATIONS: IM = intramuscular; IV = intravenous; LFT = liver function test; SC = subcutaneous.
MulTIPle SCleRoSIS CONTINUED 
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compromise between efficacy and treat-
ment burden has to be accepted. 
The dosage, adverse effects and precau-
tions for use of the immunomodulatory 
therapies currently available are sum-
marised in Table 2.
Interferon beta
Interferon beta was the first approved med-
ication for MS and has an extensive clinical 
trial evidence base. It reduces the frequency 
of relapses by about one-third. In addition, 
patients treated with interferon early in the 
course of the disease show a significant 
delay in time to disease progression. 
Interferon beta-1a is administered by 
intramuscular injection weekly or subcuta-
neous injection three times per week, and 
interferon beta-1b by subcutaneous injection 
every other day. Common adverse effects 
include ‘flu-like’ symptoms (myalgia and 
fever), injection site reactions and, possibly, 
aggravation of depression. These side effects 
may be minimised with dose titration when 
commencing the drug and the use of anti-
pyretics such as NSAIDs. Side effects decline 
over time. Haematological abnormalities 
(e.g. leucopenia, thrombocytopenia) and 
liver enzyme elevation are well documented 
but are usually transient in nature. Baseline 
liver function tests (LFTs) and full blood 
count should be performed, with follow-up 
testing typically at one, three and six months 
after interferon initiation.
Glatiramer acetate
Glatiramer acetate has comparable clinical 
efficacy to interferons for the treatment of 
MS. It does not require regular blood mon-
itoring. The most common side effects are 
injection site reactions (itching, bruising 
and lipoatrophy), and about 10% of patients 
develop infrequent systemic reactions, 
which usually occur after several months 
of treatment, are self-limited, develop 
within 15 minutes of the injection and are 
characterised by flushing, tachycardia, 
tachypnoea and anxiety.
The exact mechanisms of action of the 
interferon therapies and glatiramer acetate 
in MS are not known. 
Natalizumab
Natalizumab is the only monoclonal anti-
body approved for the treatment of MS at 
present, and in Australia a neurologist must 
initiate its use. It blocks adhesion molecules 
on lymphocytes and thereby prevents their 
migration into the brain. It reduces the 
relapse rate by 67% compared with placebo, 
and overall is very well tolerated. 
Natalizumab has been associated with 
an increased risk of developing progressive 
multifocal leucoencephalopathy (PML), a 
rare opportunistic infection of the brain 
caused by the JC virus (JCV). Infection with 
JCV in childhood is common (seropreva-
lence of 50 to 57% in the general population) 
and mostly asymptomatic, with the virus 
remaining latent in the gastrointestinal 
tract, the kidneys and the CNS. PML most 
often presents with cognitive or behavioural 
symptoms (e.g. personality change), alone 
or in association with motor, language or 
visual symptoms. The risk for PML in 
patients treated with natalizumab ranges 
from less than one in 10,000 to one in 100 
and increases with duration of treatment 
beyond two years, previous immunosup-
pressant therapy and a positive result with 
the proprietary Stratify JCV test. Therefore, 
the risks and benefits of treatment with 
natalizumab should be carefully considered 
in patients who have all three risk factors. 
On the other hand, patients who are Stratify 
JCV-negative have a very low risk of PML 
irrespective of duration of treatment and 
immunosuppressant use. Regular clinical 
and MRI follow up of patients with the 
neurologist is mandatory for therapy to 
continue. Practice points on the use of natal-
izumab are listed in the box on this page. 
Mitoxantrone
Mitoxantrone is a cytotoxic agent that was 
used for patients with rapidly worsening 
relapsing–remitting MS or secondary– 
 progressive MS. Its use has been superseded 
by newer agents such as natalizumab. It is 
recommended that all patients who have 
received mitoxantrone be monitored for 
late development of cardiac failure and 
haematological malignancy.
Fingolimod
Fingolimod is an oral immunomodulatory 
agent approved for relapsing forms of MS. 
It blocks lymphocyte egression from lymph 
nodes, reducing the number of lympho-
cytes in the peripheral blood and therefore 
their migration into the CNS. The effects 
on circulating lymphocytes are reversible, 
and cell counts return to normal within 
four to six weeks after cessation of treat-
ment. In the pivotal trial of fingolimod, the 
drug reduced the annualised relapse rate 
by 54% compared with placebo. 
Fingolimod is generally well tolerated, 
but adverse effects may include brady-
cardia and atrioventricular block, and 
monitoring for these is required for six 
hours after the first dose. Other adverse 
effects include reversible asymptomatic 
elevations of liver enzymes, macular 
oedema, reduction in forced expiratory 
NATALIZUMAB PRACTICE POINTS
Before commencement
• Perform Stratify JC virus (JCV) 
 antibody test
• Obtain baseline MRI of brain
• Perform clinical assessment
• Take history (including whether there 
has been immunosuppressive therapy 
in the past)
During treatment
• Monitor for signs typical of progressive 
multifocal leucoencephalopathy (PML)
• Perform Stratify JCV antibody test 
every six months if negative
• Perform clinical assessment at least 
every six months
• Perform MRI at intervals 
• Reassess risk/benefits after two years
High PMl risk
The risk of PML is high in patients with 
the following features:
• have been treated with natalizumab for 
longer than two years
• are Stratify JCV antibody-positive
• have had previous immunosuppressant 
therapy
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volume and an increased risk of infections 
due to marked peripheral lymphopenia. 
Nonimmunity to varicella zoster virus 
(VZV) is an absolute contraindication and 
VZV antibody testing must be performed 
prior to fingolimed’s commencement. 
Other contraindications include myo-
cardial infarction, unstable angina, stroke 
or transient ischaemic attack in the past 
six months, QTc interval longer than 500 
msec and concomitant treatment with 
class Ia or III antiarrhythmics. Caution 
must be exercised in patients with diabetes, 
hypertension and asthma. Practice points 
regarding the use of fingolimod are 
 summarised in the box on this page. 
Cladribine
Cladribine is approved in Australia for the 
treatment of MS but has been withdrawn 
from the market by the manufacturer. It 
causes lymphocyte depletion and long- 
lasting lymphopenia and its parenteral 
formulation is used for the treatment of 
hairy cell leukaemia and B-cell chronic 
lymphocytic leukaemia. 
Teriflunomide
Teriflunomide was approved in 2012 for 
the treatment of relapsing forms of MS. It 
is relatively well tolerated and is chemically 
closely related to leflunomide. It suppresses 
the proliferation and effector functions of 
activated B and T lymphocytes. It has been 
recommended for PBS listing by the 
 Pharmaceutical Benefits Advisory Com-
mittee (PBAC) and a Patient Familiarisation 
Program has been under way for many 
months.
Patients taking teriflunomide require 
ongoing blood monitoring, and adverse 
effects include liver failure, neuropathy and 
leucopenia. Importantly, there is extensive 
enterohepatic circulation of this drug and 
if rapid drug clearance is required then 
active specific intervention is necessary. It 
is rated category X for pregnancy, and men 
too must stop taking the drug if they wish 
to father a child. 
Dimethyl fumarate
Dimethyl fumarate is a new oral therapy 
that was recently approved by the TGA 
for use in patients with relapsing MS to 
reduce the frequency of relapses and to 
delay the progression of disability. It 
has been recommended for PBS listing 
by the PBAC and a Patient Familiarisation 
 Program commenced in Australia in 
October 2013. 
Dimethyl fumarate has been shown to 
significantly reduce MS disease activity, 
including relapses and development of 
brain lesions, as well as to slow disability 
progression over time. It has a favourable 
safety and tolerability profile, the most 
common adverse reactions being flushing, 
mostly mild to moderate in nature, and 
gastrointestinal symptoms (diarrhoea, 
nausea, abdominal pain). These events are 
most common at the start of therapy, and 
usually decrease over time. Dimethyl fuma-
rate may decrease lymphocyte counts. A 
full blood count should be performed 
before initiation and repeated annually or 
as clinically indicated.
Vitamin D
Vitamin D supplementation is often recom-
mended to patients with MS, although 
strong evidence for benefit has not been 
accumulated. Observational studies have 
shown an association between low serum 
vitamin D concentrations and an increased 
incidence of MS, as well as increased MS 
activity. The true relation between serum 
vitamin D concentrations and MS has yet 
to be fully elucidated. Serum vitamin D 
concentrations greater than 75 nmol/L are 
recommended, and doses of 1000 IU up to 
5000 IU daily may be necessary to maintain 
the desired serum levels. The possible 
 benefits of vitamin D are being  studied in 
Australia by the PrevANZ study, which 
commenced in 2012. 
During vitamin D supplementation, 
patients should be monitored for signs 
of toxicity as well as serum levels.
Immunomodulatory treatments 
in development
Several immunomodulatory treatments for 
MS have shown positive effects in clinical 
trials and are likely to be introduced in the 
future. These treatments include oral 
 therapies (laquinimod), as well as mono-
clonal antibody therapies (alemtuzumab, 
daclizumab and ocrelizumab). 
SYMPTOM MANAGEMENT
• Immunomodulatory therapies cannot 
alleviate already existing MS symptoms. 
They merely prevent the development of 
acute relapses.
Immunomodulatory therapies reduce 
the number of relapses in MS and reduce 
clinical progression, but cannot relieve exist-
ing symptoms (e.g. pain, spasticity and cog-
nitive problems) that the disease has already 
caused. Therefore, symptomatic treatments 
are of major importance for patients with 
MS. In many parts of Australia, the local 
chapter of the MS Society provides numer-
ous patient services, including counselling, 
immunotherapy support, physiotherapy, 
FINGOLIMOD PRACTICE POINTS
Before commencement
• Perform baseline ophthalmologic 
examination
• Perform baseline liver function tests 
and complete blood count
• Start contraception if applicable
• Perform ECG
• Perform varicella zoster virus serology 
(to confirm immunity) 
First dose
• Observe patient for six hours for 
adverse events such as bradycardia 
and atrioventricular block
During treatment
• Do not administer any live attenuated 
vaccines
• Perform ophthalmological examination 
three months after first dose
• Perform spirometric evaluation if 
 clinically indicated
• Monitor blood pressure
• Follow up liver function tests and 
 complete blood count
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occupational therapy, continence support 
and home services, and has appropriately 
trained and experienced allied health staff. 
The multidisciplinary input they are able to 
provide can be of great assistance to the 
medical practitioner caring for patients with 
this disease.
Bladder problems
Bladder problems are present in more than 
70% of patients with MS. Patients most often 
complain about urinary urgency, frequency, 
incontinence, urinary hesitancy and a 
 sensation of bladder fullness after voiding. 
In all patients presenting with bladder 
 problems, a urinary tract infection should 
be excluded as the first step. Then the blad-
der dysfunction should be categorised as 
either a failure-to-store or a failure-to-empty 
abnormality. Determination of postvoid 
residual (PVR) urine volume by ultrasound 
can help to distinguish between a failure-
to-empty (PVR urine volume > 100 mL) 
and a failure-to-store (PVR urine volume 
≤ 100 mL) dysfunction (see the flowchart 
on this page). Many patients have a mixture 
of both problems.
Failure-to-store bladder disorders may 
be treated with anticholinergic agents, 
such as oxybutynin and solifenacin. Intra-
nasal desmopressin may be used to reduce 
 nocturia but patients taking this require 
monitoring for hyponatraemia by mea-
surement of serum osmolality. Failure-
to-empty bladder  dysfunctions are best 
treated with intermittent catheterisation. 
An α-adrenergic medication, such as 
tamsulosin, can reduce PVR urine volume, 
and may be effective in some patients. 
Patients with both failure-to-store and 
failure-to-empty bladder  dysfunction may 
benefit from a combination of catheteri-
sation and anticholinergic agents. More 
complex symptoms and/or no improve-
ment may require an accurate diagnosis 
of the type of bladder or sphincter dys-
function, including urodynamics and 
urological referral. Intravesical injection of 
botulinum toxin by a urologist may be 
useful to treat refractory spastic bladder 
symptoms.
Bowel problems
Bowel dysfunction, including constipation 
or faecal incontinence, may occur in 
patients with MS. Constipation can be 
worsened by anticholinergic medication 
used for bladder problems, and also by 
antispasticity and antidepressant agents. 
Pain
It is important to distinguish between pri-
mary pain due to the demyelinating process 
itself, and secondary musculoskeletal pain. 
• Primary pain is characterised by a 
burning discomfort, or has a gnawing 
or shooting quality. Tricyclic anti-
depressants (such as amitriptyline and 
dothiepin) may be used as first-line 
treatment, but may exacerbate bladder 
dysfunction. The anticonvulsants 
gabapentin and pregabalin and the 
serotonin and noradrenaline reuptake 
inhibitors duloxetine and venlafaxine 
may also be used. First-line treatment 
for trigeminal neuralgia is carbamaz-
epine, with other drugs being  
relatively ineffective. 
• Secondary pain can arise due to poor 
posture, poor balance or the abnormal 
use of muscles and joints as a result of 
spasticity. Musculoskeletal pain is 
treated as in patients who do not 
have MS.
Spasticity
Besides pain, spasticity can lead to contrac-
tures and decubitus. The therapeutic 
approach should include physical and occu-
pational therapy, stretching and exercise 
in addition to pharmacotherapy. 
The first-line drug is the muscle relaxant 
baclofen, which must be slowly titrated from 
10 mg to 140 mg per day in three to four 
divided doses. Side effects include sedation 
and increased muscle weakness, which may 
negatively affect gait. 
Second-line agents include benzodiaz-
epines, such as diazepam and clonazepam. 
Additional treatments for more severe spas-
ticity management include intramuscular 
botulinum toxin injection and intrathecal 
baclofen pump placement. Controlled 
release fampridine may also benefit patients 
AN APPRoACH To BlADDeR PRoBleMS IN PATIeNTS 
WITH MulTIPle SCleRoSIS
Consider anticholinergic agents, 
e.g. oxybutynin and solifenacin
Consider catheterisation
Failure-to-store dysfunction Failure-to-empty dysfunction
Patient with MS presents with urinary 
urgency and frequency
Measure postvoid residual (PVR) urine volume
PVR urine volume ≤ 100 mL PVR urine volume > 100 mL
Exclude urinary tract infection
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with spasticity, improving their walking 
speed and reducing fatigue. Fampridine is 
not currently subsidised by the PBS and its 
cost may be prohibitive for many patients.
Fatigue
• Increased effort to overcome a higher 
muscle tone in spasticity may increase 
fatigue.
Fatigue is an overwhelming sense of 
tiredness and lack of energy, and is difficult 
to measure objectively. Nearly every patient 
with MS experiences fatigue to some 
degree, and one-third of them consider 
fatigue as the most troublesome of all symp-
toms. Fatigue can be the leading cause of 
inability to work and disruption of family 
and social life. 
There is an overlap between the fatigue 
of MS and affective disorder, and many 
patients will benefit from the use of a selec-
tive serotonin reuptake inhibitor (SSRI) such 
as fluoxetine or escitalopram. Amantadine 
may also be used on an empirical basis.
Depression
• Symptoms can influence each other in 
a negative way – for example, depression 
negatively affects cognition. 
Major depression is the most common 
mood disorder associated with MS, and 
approximately 50% of patients with the 
disease are treated for depression at some 
stage. The GP must remain vigilant for 
depression in patients with MS. SSRIs are 
used as first-line agents. 
Cognitive dysfunction
Cognitive impairment is frequent in patients 
with MS. It may already be present in the 
early disease stages, and may occur in the 
absence of significant physical  disability. 
Cognitive problems mainly affect attention, 
concentration, short-term memory, infor-
mation processing, visuospatial perception 
and verbal fluency. Although cognitive 
impairment can have significant impact on 
activities of daily life (driving, cooking, work 
performance), it often remains unrecognised. 
Cognitive dysfunction is one of the major 
causes for loss of employment and, along 
with affective  disorder, is a significant factor 
in family breakdown.
MS CONTROVERSIES
Patients with MS frequently ask about or 
actively pursue unscientific and sometimes 
fraudulent putative therapies, and they are 
vulnerable to exploitation. 
CCSVI 
Patients may ask about ‘CCSVI’ (chronic 
cerebrospinal venous insufficiency) and 
MS. There is no scientific evidence for the 
efficacy of widening the cerebrospinal 
veins with angioplasty in patients with MS, 
and no reproducible randomised scientific 
evidence is able to associate these putative 
venous abnormalities with the occurrence, 
severity or progression of MS. Indeed, the 
converse is true. 
Low-dose naltrexone
Similarly, there is no validated or randomised 
evidence to support the use of low-dose nal-
trexone in MS. Also, this drug is not licensed 
for MS and its use is not without hazard. 
Diet
The evidence for the role of diet in MS is 
complex and unclear. Some uncontrolled 
observational studies have suggested that a 
low-fat diet may be beneficial, but careful 
case-control studies have not shown such a 
link. Some authors have proposed a high-fat 
so-called ‘caveman diet’. The potential for 
significant confounders in the analysis of 
the relation between diet and MS is enor-
mous, and until further evidence is available 
a healthy balanced diet remains appropriate 
advice. 
CONCLUSION
The GP plays a pivotal role in the manage-
ment of patients with MS and is usually 
the first point of contact when patients 
have symptoms or complications of either 
the disease or its treatment. Patients with 
MS often require high levels of medical 
input from both their GP and their treat-
ing  neurologist. Knowledge of MS, its 
 symptomatic therapies and the various 
 disease-modifying therapies are pivotal in 
understanding the problems that patients 
with MS may encounter, and also facilitates 
effective communication between the 
patient, GP and neurologist.  MT 
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